News and Articles
Follow A Race Against Blindness research funding, inherited retinal disease developments, community stories, grant announcements, and updates from families racing toward sight-saving treatments.
Featured article
A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)
Newly added funding closes critical gap and enables planned trial initiation in early 2026
Latest Posts
🧡 Gratitude Gallery: New Reviews & Experiences From Our Community
This Gratitude Gallery shares real reviews and experiences from our community—honest messages of hope, faith, and resilience that remind us why this mission matters.
🧡 Gratitude Gallery: A Christmas Miracle in the Making
This special Gratitude Gallery shares real reviews and experiences from our community following a Christmas Eve message—expressions of hope, faith, and belief in miracles unfolding.
FDA Approves First Gene Therapy for Wiskott-Aldrich Syndrome — A Major Milestone for Rare Disease Treatment
The FDA has approved the first-ever gene therapy for Wiskott-Aldrich syndrome, marking a major milestone for the rare disease community. While this treatment is not for vision loss, it represents important progress for gene therapy as a whole — and brings renewed hope for families awaiting treatments for inherited retinal diseases like BBS and retinitis pigmentosa.
Beacon Therapeutics Treats First Patient in New Gene Therapy Trial for X-Linked Retinitis Pigmentosa
Beacon Therapeutics has treated the first patient in a new clinical trial evaluating bilateral gene therapy for X-linked retinitis pigmentosa. This milestone builds on encouraging earlier data and represents continued momentum in retinal gene therapy research — bringing renewed hope to families affected by inherited retinal diseases.
BBS1 Gene Therapy Clinical Trial Receives MHRA Approval: A Major Milestone for the BBS Community